Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 31fludarabine 28Whole-Body Irradiation 18Mycophenolic Acid 18venetoclax 14Tacrolimus 14fludarabine phosphate 13Standard of Care 13Specimen Handling 10Practice Guidelines as Topic 10Melphalan 10Busulfan 10Sirolimus 9Thiotepa 8Interviews as Topic 8Azacitidine 8Educational Status 7trametinib 6Surveys and Questionnaires 6Methods 6Mesna 6Biopsy 6thymoglobulin 5Rituximab 5Magnetic Resonance Spectroscopy 5Filgrastim 5Early Intervention, Educational 5Behavior Therapy 5Antilymphocyte Serum 5Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Inotuzumab Ozogamicin × 1 year × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡